Drug Profile
Quaratusugene ozeplasmid - Genprex/University of Texas M D Anderson Cancer Center
Alternative Names: CNVN 202; DOTAP Chol-TUSC2 Liposomal Complex; DOTAP-Chol-fus1; DOTAP-Cholesterol-Fus1 liposome complex; FUS1 cancer gene therapy; GPX 001; INGN-401; ONC-001; ONC-002; ONC-003; ONC-004; Oncoprex; REQORSA; TUSC2 immunogene therapy; TUSC2-nanoparticlesLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Genprex; National Cancer Institute (USA); University of Texas M. D. Anderson Cancer Center
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; TUSC2 protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-small cell lung cancer; Small cell lung cancer
- Discontinued Triple negative breast cancer
Most Recent Events
- 12 Mar 2024 Genprex has patent protection for Quaratusugene ozeplasmid in South Korea
- 06 Mar 2024 Pharmacodynamics data from preclinical trial in Non small cell lung cancer released by Genprex
- 02 Feb 2024 Phase-I/II clinical trials in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT05703971)